Amicus Therapeutics’ (FOLD) Overweight Rating Reaffirmed at Cantor Fitzgerald

Cantor Fitzgerald reissued their overweight rating on shares of Amicus Therapeutics (NASDAQ:FOLD) in a report published on Friday morning, Benzinga reports. Cantor Fitzgerald currently has a $20.00 price objective on the biopharmaceutical company’s stock.

Several other research analysts also recently weighed in on the stock. Needham & Company LLC reissued a hold rating on shares of Amicus Therapeutics in a research note on Friday, August 9th. Wells Fargo & Company assumed coverage on shares of Amicus Therapeutics in a research note on Thursday, May 30th. They set an overweight rating and a $18.00 price objective on the stock. JPMorgan Chase & Co. decreased their target price on shares of Amicus Therapeutics from $17.00 to $16.00 and set an overweight rating on the stock in a research report on Friday, August 16th. Finally, Jefferies Financial Group assumed coverage on Amicus Therapeutics in a report on Friday, September 6th. They issued a buy rating and a $18.00 price target for the company. Two equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of Moderate Buy and an average price target of $17.00.

Amicus Therapeutics Price Performance

Shares of NASDAQ FOLD opened at $11.22 on Friday. The company has a current ratio of 2.75, a quick ratio of 2.26 and a debt-to-equity ratio of 2.93. The company’s 50-day moving average price is $11.05 and its 200 day moving average price is $10.69. Amicus Therapeutics has a 52 week low of $9.02 and a 52 week high of $14.57. The stock has a market cap of $3.32 billion, a price-to-earnings ratio of -22.90 and a beta of 0.69.

Amicus Therapeutics (NASDAQ:FOLD) last released its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.05) EPS for the quarter, meeting the consensus estimate of ($0.05). Amicus Therapeutics had a negative net margin of 26.23% and a negative return on equity of 41.47%. The business had revenue of $126.67 million for the quarter, compared to analyst estimates of $121.21 million. During the same period in the prior year, the business earned ($0.15) earnings per share. The company’s quarterly revenue was up 34.0% on a year-over-year basis. As a group, research analysts forecast that Amicus Therapeutics will post -0.08 earnings per share for the current fiscal year.

Insider Activity

In related news, CEO Bradley L. Campbell sold 6,100 shares of Amicus Therapeutics stock in a transaction on Friday, July 5th. The stock was sold at an average price of $10.00, for a total value of $61,000.00. Following the transaction, the chief executive officer now owns 886,654 shares in the company, valued at $8,866,540. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In other news, CEO Bradley L. Campbell sold 7,500 shares of the stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $11.71, for a total value of $87,825.00. Following the completion of the sale, the chief executive officer now owns 886,654 shares of the company’s stock, valued at $10,382,718.34. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Bradley L. Campbell sold 6,100 shares of the firm’s stock in a transaction on Friday, July 5th. The shares were sold at an average price of $10.00, for a total transaction of $61,000.00. Following the completion of the transaction, the chief executive officer now directly owns 886,654 shares in the company, valued at approximately $8,866,540. The disclosure for this sale can be found here. Insiders sold 21,100 shares of company stock valued at $226,375 in the last ninety days. Company insiders own 2.20% of the company’s stock.

Institutional Trading of Amicus Therapeutics

Large investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. lifted its stake in shares of Amicus Therapeutics by 5.0% during the fourth quarter. Vanguard Group Inc. now owns 28,492,486 shares of the biopharmaceutical company’s stock worth $404,308,000 after purchasing an additional 1,360,613 shares in the last quarter. Perceptive Advisors LLC lifted its position in Amicus Therapeutics by 1.3% during the 4th quarter. Perceptive Advisors LLC now owns 28,057,456 shares of the biopharmaceutical company’s stock worth $398,135,000 after acquiring an additional 364,539 shares in the last quarter. Wellington Management Group LLP boosted its holdings in Amicus Therapeutics by 101.9% in the 4th quarter. Wellington Management Group LLP now owns 15,190,024 shares of the biopharmaceutical company’s stock worth $215,546,000 after acquiring an additional 7,666,335 shares during the period. Janus Henderson Group PLC grew its position in Amicus Therapeutics by 20.1% in the first quarter. Janus Henderson Group PLC now owns 13,814,514 shares of the biopharmaceutical company’s stock valued at $162,713,000 after acquiring an additional 2,307,385 shares in the last quarter. Finally, William Blair Investment Management LLC raised its stake in shares of Amicus Therapeutics by 12.8% during the second quarter. William Blair Investment Management LLC now owns 13,003,363 shares of the biopharmaceutical company’s stock valued at $128,993,000 after purchasing an additional 1,477,084 shares during the period.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.